Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 13/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 11/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557159 | 0.84 | ALKBH2 (0.47) | KITDDR1PDE4BPDE4DNAPRT | |
| SCHEMBL25419641 | 0.83 | LMNA (0.54) | KITDDR1PDE4BPDE4DNTRK1 | |
| SCHEMBL30708693 | 0.81 | LMNA (0.53) | KITDDR1PDE4BPDE4DNTRK1 | |
| SCHEMBL18825814 | 0.79 | NTRK1 (0.47) | KITDDR1NTRK1DDR2 | |
| SCHEMBL2448509 | 0.75 | ABL1 (0.41) | KITDDR1PDE4BPDE4DNTRK1 | |
| SCHEMBL3611630 | 0.75 | MAP4K4 (0.46) | KITDDR1LMNA | |
| SCHEMBL7067259 | 0.73 | TP53 (0.43) | KITDDR1NTRK1 | |
| SCHEMBL15019947 | 0.72 | KIT (0.37) | KITDDR1PDE4BPDE4D | |
| SCHEMBL12872518 | 0.72 | GAA (0.38) | KITDDR1PDE4BPDE4DDDR2 | |
| SCHEMBL25239960 | 0.70 | KIT (0.46) | KITDDR1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | IMBACH PATRICIA | 2010-03-18 | — | — | US | disclosed |
| EP-1918291-A1 | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069395-A1 | Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors | PRKCA, PRKACA, MAP3K19 | KIT 547/4885DDR1 996/4885PDE4B 598/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | KIT 4683/4885DDR1 3686/4885PDE4B 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.